Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of SPARC_147709- Test and Reference, 2mg/ml (30 mg/m2 Dose) in Patients With Multiple Myeloma

NCT00863174 is registered in ClinicalTrials.gov with Sun Pharma Advanced Research Company Limited as lead sponsor.

NCT NCT00863174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00863174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of SPARC_147709- Test and Reference, 2mg/ml (30 mg/m2 Dose) in Patients With Multiple Myeloma
Lead sponsor
Sun Pharma Advanced Research Company Limited
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2010
Completion date
April 30, 2011
Enrollment
24 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma